Austar Lifesciences Limited AULSF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.69% | 7.88% | 2.21% | -1.88% | -5.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.69% | 7.88% | 2.21% | -1.88% | -5.27% |
| Cost of Revenue | 16.61% | 9.92% | 3.40% | -1.99% | -6.58% |
| Gross Profit | 2.11% | -0.20% | -2.52% | -1.43% | 0.27% |
| SG&A Expenses | -2.14% | -4.52% | -6.90% | -9.82% | -11.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 10.32% | 22.52% | 34.08% | 4.31% | -39.34% |
| Total Operating Expenses | 13.45% | 7.50% | 1.69% | -3.65% | -8.12% |
| Operating Income | 22.97% | 23.63% | 24.15% | 206.11% | 489.15% |
| Income Before Tax | -13.23% | 33.85% | 126.90% | 3,556.75% | 324.95% |
| Income Tax Expenses | 93.29% | 96.95% | 101.16% | 121.83% | 169.22% |
| Earnings from Continuing Operations | -43.22% | 10.97% | 141.32% | 864.49% | 248.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -139.99% | -99.14% | -63.68% | -42.67% | -24.48% |
| Net Income | -49.29% | 0.85% | 109.39% | 233.87% | 152.06% |
| EBIT | 22.97% | 23.63% | 24.15% | 206.11% | 489.15% |
| EBITDA | 12.96% | 12.74% | 12.42% | 66.64% | 259.36% |
| EPS Basic | -50.00% | 0.00% | 109.09% | 236.23% | 152.75% |
| Normalized Basic EPS | -6.25% | 42.86% | 135.29% | 7,100.00% | 300.00% |
| EPS Diluted | -52.08% | -1.45% | 114.29% | 230.99% | 152.17% |
| Normalized Diluted EPS | -6.25% | 42.86% | 135.29% | 7,100.00% | 300.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |